San Diego, California
United States
58
2026-04-30
The entities that hold a legal rights for patent applications filed by inventor Davis Robert E.:
Robert E. Davis from San Diego, US has applied for patents for these inventions. The list has both pending applications and granted patents:
METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR
#2 | 2026-02-26NOVEL USES
#3 | 2026-02-26NOVEL METHODS
#4 | 2025-12-18ORGANIC COMPOUND
#5 | 2025-10-16ORGANIC COMPOUNDS
#6 | 2025-06-19NOVEL METHODS
#7 | 2025-06-12ORGANIC COMPOUNDS
#8 | 2025-03-27ORGANIC COMPOUNDS
#9 | 2025-03-20ORGANIC COMPOUND
#10 | 2025-03-20USES
#11 | 2024-12-19NOVEL METHODS
#12 | 2024-10-03ORGANIC COMPOUND
#13 | 2024-04-18NOVEL METHODS
#14 | 2024-03-21SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
#15 | 2024-01-04Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
#16 | 2023-12-28ORGANIC COMPOUNDS
#17 | 2023-11-23NOVEL METHODS
#18 | 2023-01-264-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
#19 | 2022-11-17NOVEL METHODS
#20 | 2022-09-08ORGANIC COMPOUNDS
#21 | 2022-08-04SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
#22 | 2021-12-09Uses
#23 | 2021-12-02NOVEL USES
#24 | 2021-06-24METHODS OF SCHIZOPHRENIA TREATMENT
#25 | 2020-10-15SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
#26 | 2019-01-31Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#27 | 2017-07-27Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#28 | 2016-09-01Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#29 | 2015-07-23Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#30 | 2014-05-22Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#31 | 2013-05-30Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#32 | 2012-11-01Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#33 | 2011-10-20Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#34 | 2010-09-09Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#35 | 2010-09-09Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#36 | 2009-10-13Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#37 | 2009-08-20ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY
#38 | 2009-06-18Selective serotonin receptor inverse agonists as therapeutics for disease
#39 | 2008-02-28USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS
#40 | 2007-01-25Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
#41 | 2006-11-23Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#42 | 2006-11-23Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#43 | 2006-09-07Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
#44 | 2006-02-28Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
#45 | 2005-12-29Selective serotonin receptor inverse agonists as therapeutics for disease
#46 | 2005-11-24Selective serotonin receptor inverse agonists as therapeutics for disease
#47 | 2005-11-24Selective serotonin receptor inverse agonists as therapeutics for disease
#48 | 2005-07-07Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
#49 | 2005-06-23Treating neuropathic pain with neuropeptide FF receptor 2 agonists
#50 | 2005-06-16Muscarinic M1 receptor agonists for pain management
#51 | 2005-06-14Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
#52 | 2005-06-07Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
#53 | 2005-05-31Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
#54 | 2005-03-24Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
#55 | 2005-03-15Method of targeting conjugate molecules to mitochondria
#56 | 2005-01-27Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
#57 | 2005-01-06Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor.
#58 | 2005-01-06Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
770125 ⎘